Pilot Gene Technology (Hangzhou) Co., Ltd.
PrivateLast Round
Series B
Sep 1, 2023
Total Funding Raised
$35.2M
Company Overview
Pilot Gene Technology (Hangzhou) Co., Ltd. operates in Healthcare & Life Sciences and is based in Hangzhou. Its latest recorded funding round was a Series B round in September 2023.
Pilot Gene Technology (Hangzhou) Co., Ltd. is a biotechnology company that develops digital polymerase chain reaction (PCR) systems and molecular diagnostic solutions for clinical and research applications.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pilot Gene Technology (Hangzhou) Co., Ltd. Comparables
Compare Pilot Gene Technology (Hangzhou) Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Suzhou Sniper Medical Technologies Co., Ltd. | 92% | |
| TargetingOne Corporation | 91% | |
| Zhenzhun Bio-Tech | 86% |
For institutional investors. Book with your work email.
Pilot Gene Technology (Hangzhou) Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 1, 2023 | ||||
| Series A Extension | Jul 19, 2021 | ||||
| Series A | Jan 12, 2018 |
For institutional investors. Book with your work email.
Pilot Gene Technology (Hangzhou) Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Shenzhen Dachen Caizhi Venture Capital Management | Series A Extension |
| Share Capital | Series B, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 18, 2025
Attending MEDICA 2025 to showcase rapid sepsis diagnosis.
- Nov 15, 2025
Grew 300% QoQ from 1 to 4 employees.
For institutional investors. Book with your work email.
Pilot Gene Technology (Hangzhou) Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Pilot Gene Technology (Hangzhou) Co., Ltd.'s valuation, stock price, and market status.
Is Pilot Gene Technology (Hangzhou) Co., Ltd. a public or private company?
Pilot Gene Technology (Hangzhou) Co., Ltd. is a private company.
What is the current stock price of Pilot Gene Technology (Hangzhou) Co., Ltd.?
Pilot Gene Technology (Hangzhou) Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Pilot Gene Technology (Hangzhou) Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Pilot Gene Technology (Hangzhou) Co., Ltd. worth (valuation)?
Valuation information for Pilot Gene Technology (Hangzhou) Co., Ltd. is not publicly available.
Can I buy Pilot Gene Technology (Hangzhou) Co., Ltd. stock?
Pilot Gene Technology (Hangzhou) Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Pilot Gene Technology (Hangzhou) Co., Ltd.'s last funding round?
Pilot Gene Technology (Hangzhou) Co., Ltd.'s most recent funding round was Series B on September 1, 2023.
Who are the main investors in Pilot Gene Technology (Hangzhou) Co., Ltd.?
Key investors in Pilot Gene Technology (Hangzhou) Co., Ltd. include Share Capital.
Will Pilot Gene Technology (Hangzhou) Co., Ltd. IPO soon?
No public IPO plans have been announced for Pilot Gene Technology (Hangzhou) Co., Ltd..
How can I track Pilot Gene Technology (Hangzhou) Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Pilot Gene Technology (Hangzhou) Co., Ltd.'s shares on secondary markets.